Tag Archives: astrazeneca

Patent

BDR, Lee Pharma decide not to pursue CL appeals


(Posted on behalf of Balaji) A  Reuters report from earlier today, carried by newspapers such as Mint and The Hindu, states that generics manufacturers Lee Pharma and BDR have decided not to pursue appeals against the rejection of their compulsory license applications for patents over AstraZeneca’s Saxagliptin and BMS’s Dasatinib respectively. The report identifies recent news of the Indian government’s private assurance to US pharma lobbies that it would not issue compulsory licenses for commercial purposes as the reason behind the decision. If true, the ramifications of this development for…


Read More »
Trademark

AstraZeneca v. Dr. Reddy’s – Colour as a Pharmaceutical Trade Dress


“You take the blue pill and the story ends. You wake in your bed and believe whatever you want to believe. You take the red pill and you stay in Wonderland and I show you how deep the rabbit-hole goes.” Morpheus, The Matrix. US-based pharma AstraZeneca had, not so long ago, filed a suit before a Delaware court against the purple colour of the generic version of AstraZenca’s antacid pill, Nexium, being sold by Dr. Reddy’s Laboratories in the US….


Read More »